BACKGROUND/AIM: To evaluate the efficacy of oxaliplatin plus fluorouracil and leucovorin (FOLFOX) on initially unresectable colorectal liver metastases (CRLM). PATIENTS AND METHODS: From May 2005 to December 2008, FOLFOX was administered to 71 patients with initially unresectable CRLM. Hepatic resection was performed promptly after CRLM became resectable. RESULTS: Twenty-six patients (37%) were downstaged as being resectable. The mean interval between the first FOLFOX and hepatic resection was six months (range, 3-7 months), and 7.1 courses (range, 2-12). Operative morbidity was 12% and mortality was nil. The median progression-free survival time was 19 and 7 months, and the median survival time was over 48 and 20 months, in finally resectable and unresectable patients, respectively. Multivariate analysis revealed that additional hepatic resection was the only independent prognostic factor (hazard ratio 4.80, p<0.01). CONCLUSION: FOLFOX is an effective chemotherapeutic regimen leading to successful hepatic resection and an excellent prognosis for patients with initially CRLM.
BACKGROUND/AIM: To evaluate the efficacy of oxaliplatin plus fluorouracil and leucovorin (FOLFOX) on initially unresectable colorectal liver metastases (CRLM). PATIENTS AND METHODS: From May 2005 to December 2008, FOLFOX was administered to 71 patients with initially unresectable CRLM. Hepatic resection was performed promptly after CRLM became resectable. RESULTS: Twenty-six patients (37%) were downstaged as being resectable. The mean interval between the first FOLFOX and hepatic resection was six months (range, 3-7 months), and 7.1 courses (range, 2-12). Operative morbidity was 12% and mortality was nil. The median progression-free survival time was 19 and 7 months, and the median survival time was over 48 and 20 months, in finally resectable and unresectable patients, respectively. Multivariate analysis revealed that additional hepatic resection was the only independent prognostic factor (hazard ratio 4.80, p<0.01). CONCLUSION:FOLFOX is an effective chemotherapeutic regimen leading to successful hepatic resection and an excellent prognosis for patients with initially CRLM.
Authors: Akshat Saxena; Lourens Bester; Leonard Shan; Marlon Perera; Peter Gibbs; Baerbel Meteling; David L Morris Journal: J Cancer Res Clin Oncol Date: 2013-12-07 Impact factor: 4.553
Authors: Michael I DʼAngelica; Camilo Correa-Gallego; Philip B Paty; Andrea Cercek; Alexandra N Gewirtz; Joanne F Chou; Marinella Capanu; T Peter Kingham; Yuman Fong; Ronald P DeMatteo; Peter J Allen; William R Jarnagin; Nancy Kemeny Journal: Ann Surg Date: 2015-02 Impact factor: 12.969
Authors: M-A Allard; Y Nishioka; N Beghdadi; K Imai; M Gelli; S Yamashita; Y Kitano; T Kokudo; Y-I Yamashita; A Sa Cunha; E Vibert; D Elias; D Cherqui; D Goere; R Adam; H Baba; K Hasegawa Journal: BJS Open Date: 2019-05-14